BIOPSYCHOSOCIAL CHANGES IN POST-TREATMENT PERIOD OF BREAST CANCER

2013 ◽  
Author(s):  
Figen Sengun Inan ◽  
Besti Ustun
Keyword(s):  
Breast Cancer ◽  
Treatment Period ◽  
Post Treatment

scholarly journals Self Resiliency Process: Breast Cancer Survivor (Post-Treatment)

Khazanah ◽  
2020 ◽  
Vol 12 (2) ◽  
Author(s):  
Zulfah Purwina ◽  
Keyword(s):  
Breast Cancer ◽  
Treatment Period ◽  
Breast Cancer Survivor ◽  
Qualitative Method ◽  
Breast Cancer Survivors ◽  
Post Treatment ◽  
Process Pattern ◽  
Open Coding ◽  
Problem Formulations ◽  
Axial Coding

Background: Cancer is one of the most deadly diseases. Many cancer sufferers cannot cope with stress after going through the treatment period or post-treatment. Self-resiliency power is an important component for the success of individuals to carry out life after treatment. The ability of self-resiliency power possessed by each individual varies and is unique to each other.The purpose of this study was to look at and explore more deeply about the process of arousing self resiliency in post-treatment survivors of breast cancer. Method: This study uses a qualitative method of grounded theory involving 3 (three) survivors of breast cancer as participants of the study. Result: The results of the present study indicate that I found an interesting theme from the open coding, axial coding and selective coding process. Conclusion: The results of this study answered questions and problem formulations because they had found patterns of self-resiliency in post-treatment breast cancer survivors. Each participant is unique so that the process pattern of their self-resiliency is different.

CONTRACEPTION BY AN INJECTABLE LONG-ACTING OESTROGEN-PROGESTOGEN AGENT. III

1972 ◽  
Vol 69 (1) ◽  
pp. 67-76
Author(s):  
Rolf Plesner
Keyword(s):  
Treatment Period ◽  
Treatment Cycle ◽  
Post Treatment ◽  
Mixed Phase ◽  
Discontinuation Of Treatment ◽  
Phase Type ◽  
Secretory Type ◽  
Pre Treatment ◽  
Long Acting ◽  
Fertile Women

ABSTRACT Twenty-two fertile women were treated cyclically in from 4–30 cycles (mean 15.5) with a total of 341 injections of Deladroxate®, an injectable, long-acting oestrogen-progestogen. The injections were administered on the 8th (7th–9th) day of each cycle. Before treatment, the last pre-treatment cycle was controlled by means of daily recordings of the basal body temperature (BBT), urinary excretion of pregnanediol and total pituitary gonadotrophins at certain intervals, and by endometrial biopsies obtained late in the cycle. The effects of Deladroxate® on ovulation, on pituitary gonadotrophic function, and on the endometrium were controlled by the above mentioned parameters during cycles 1, 3, and 6, and all assessments were repeated after discontinuation of treatment. During treatment, there was a statistically significant fall in gonadotrophin excretion values (as compared with the pre-treatment values), and the fall was found to be gradually progressive during treatment. After discontinuation of treatment, there seemed to be a tendency towards an increase in the excretion values. Suppression of ovulation as determined by means of the pregnanediol excretion during treatment, was effective in nearly all of the treatment cycles checked. The fall in pregnanediol excretion was also gradually progressive during treatment, while there was a slight increase in excretion values in the post-treatment period. During treatment, 79 BBT curves were recorded. Nearly 50 % were monophasic, indicating anovulatory cycles, 17 curves were biphasic, but with the rise in temperature occurring at non-characteristic times in the cycles, 18 curves were classified as thermogenic because of a rise in temperature occurring within 24 hours after the injection, and 5 curves were not assessable. During the first month after discontinuation of treatment, 8 out of 10 recorded curves were monophasic. Out of 53 endometrial biopsies obtained around the 23rd day of the cycle, 31 were of the mixed phase type, but showing a predominance of proliferative patterns, 15 were of the secretory type, and 7 were purely proliferative. Out of 15 biopsies obtained in the post-treatment period, only two were of the mixed phase type, 12 were proliferative and one was purely secretory.

scholarly journals Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1685
Author(s):  
Antonino Grassadonia ◽  
Vincenzo Graziano ◽  
Laura Iezzi ◽  
Patrizia Vici ◽  
Maddalena Barba ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Disease Free Survival ◽  
Post Treatment ◽  
Neutrophil To Lymphocyte Ratio ◽  
Luminal Breast Cancer ◽  
Luminal A ◽  
Luminal B ◽  
Lymphocyte Ratio ◽  
Cell Counts ◽  
Pre Treatment

The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models were used for statistical analyses. Patients with pre-treatment NLRlow showed a significantly shorter DFS (HR: 6.97, 95% CI: 1.65–10.55, p = 0.002) and OS (HR: 7.79, 95% CI: 1.25–15.07, p = 0.021) compared to those with NLRhigh. Non-ductal histology, luminal B subtype, and post-treatment Ki67 ≥ 14% were also associated with worse DFS (p = 0.016, p = 0.002, and p = 0.001, respectively). In a multivariate analysis, luminal B subtype, post-treatment Ki67 ≥ 14%, and NLRlow remained independent prognostic factors for DFS, while only post-treatment Ki67 ≥ 14% and NLRlow affected OS. The present study provides evidence that pre-treatment NLRlow helps identify women at higher risk of recurrence and death among patients affected by luminal breast cancer treated with NACT.

scholarly journals PO80 Addressing the unique psychosocial needs of young women with breast cancer post-treatment

The Breast ◽  
2012 ◽  
Vol 21 ◽  
pp. S26
Author(s):  
J. Rowe ◽  
S. Lewis ◽  
M. Esser ◽  
M. McCann ◽  
N. Singh
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Post Treatment ◽  
Psychosocial Needs

Acupuncture Versus Venlafaxine for the Management of Vasomotor Symptoms in Patients With Hormone Receptor–Positive Breast Cancer: A Randomized Controlled Trial

2010 ◽  
Vol 28 (4) ◽  
pp. 634-640 ◽  
Author(s):  
Eleanor M. Walker ◽  
Alba I. Rodriguez ◽  
Beth Kohn ◽  
Ronald M. Ball ◽  
Jan Pegg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trial ◽  
Adverse Effects ◽  
Controlled Trial ◽  
Hot Flashes ◽  
Well Being ◽  
Post Treatment ◽  
Acupuncture Group ◽  
Vasomotor Symptoms ◽  
Randomized Controlled

Purpose Vasomotor symptoms are common adverse effects of antiestrogen hormone treatment in conventional breast cancer care. Hormone replacement therapy is contraindicated in patients with breast cancer. Venlafaxine (Effexor), the therapy of choice for these symptoms, has numerous adverse effects. Recent studies suggest acupuncture may be effective in reducing vasomotor symptoms in menopausal women. This randomized controlled trial tested whether acupuncture reduces vasomotor symptoms and produces fewer adverse effects than venlafaxine. Patients and Methods Fifty patients were randomly assigned to receive 12 weeks of acupuncture (n = 25) or venlafaxine (n = 25) treatment. Health outcomes were measured for up to 1 year post-treatment. Results Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment. These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine. By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels. The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects. Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being. Conclusion Acupuncture appears to be equivalent to drug therapy in these patients. It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.

Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment

2021 ◽  
Vol 28 (3) ◽  
pp. 191-201
Author(s):  
Tim Schauer ◽  
Anne-Sophie Mazzoni ◽  
Anna Henriksson ◽  
Ingrid Demmelmaier ◽  
Sveinung Berntsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Exercise Intensity ◽  
Interleukin 1 ◽  
Secondary Analysis ◽  
Post Treatment ◽  
Moderate Intensity ◽  
Post Intervention ◽  
Necrosis Factor Alpha ◽  
Markers Of Inflammation

Exercise training has been hypothesized to lower the inflammatory burden for patients with cancer, but the role of exercise intensity is unknown. To this end, we compared the effects of high-intensity (HI) and low-to-moderate intensity (LMI) exercise on markers of inflammation in patients with curable breast, prostate and colorectal cancer undergoing primary adjuvant cancer treatment in a secondary analysis of the Phys-Can randomized trial (NCT02473003). Sub-group analyses focused on patients with breast cancer undergoing chemotherapy. Patients performed 6 months of combined aerobic and resistance exercise on either HI or LMI during and after primary adjuvant cancer treatment. Plasma taken at baseline, immediately post-treatment and post-intervention was analyzed for levels of interleukin 1 beta (IL1B), IL6, IL8, IL10, tumor-necrosis factor alpha (TNFA) and C-reactive protein (CRP). Intention-to-treat analyses of 394 participants revealed no significant between-group differences. Regardless of exercise intensity, significant increases of IL6, IL8, IL10 and TNFA post-treatment followed by significant declines, except for IL8, until post-intervention were observed with no difference for CRP or IL1B. Subgroup analyses of 154 patients with breast cancer undergoing chemotherapy revealed that CRP (estimated mean difference (95% CI): 0.59 (0.33; 1.06); P  = 0.101) and TNFA (EMD (95% CI): 0.88 (0.77; 1); P  = 0.053) increased less with HI exercise post-treatment compared to LMI. Exploratory cytokine co-regulation analysis revealed no difference between the groups. In patients with breast cancer undergoing chemotherapy, HI exercise resulted in a lesser increase of CRP and TNFA immediately post-treatment compared to LMI, potentially protecting against chemotherapy-related inflammation.

Sign in / Sign up

Export Citation Format

Share Document